跳至主要内容
临床试验/NCT03727698
NCT03727698招募中不适用

Prospective Evaluation of Radiotherapy Using Magnetic Resonance Image Guided Treatment

Institute of Cancer Research, United Kingdom1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2019年1月11日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
200
试验地点
1
主要终点
Technical feasibility of undertaking MRL based radiotherapy at multiple clinical sites: The percentage of treatment fractions delivered successfully on the MR linac

研究概览

简要总结

The purpose of PERMIT is to collect information on the treatment of radiotherapy patients using a new radiotherapy machine that includes magnetic Resonance (MR) imaging (MR linac) to guide treatment. The aim is to use this information to support the introduction of MR Linac into clinical practice.

PERMIT will collect details on patients treated on the MR linac plus details on their side effects and other outcomes. This information plus technical and imaging information will be combined with information from other centres using this machine. By doing so this will help us learn how best to use the MR Linac in the future and design new radiotherapy protocols

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
5 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Radiotherapy treatment suitable to be delivered on the MR Linac.
  • Patient provides written, informed consent and/or authorization.
  • Patients between the ages of 5 and under 16 years old may enter protocol with parental/guardian consent.

排除标准

  • Contra-indications to MR imaging.
  • Radiotherapy not suitable for delivery on the MR Linac e.g. those with extended field lengths (exceeding 20 cm).

结局指标

主要结局

Technical feasibility of undertaking MRL based radiotherapy at multiple clinical sites: The percentage of treatment fractions delivered successfully on the MR linac

时间窗: 2 years

The percentage of treatment fractions delivered successfully on the MR linac, if more than 20 % of patients (depending on treatment site) need to be treated on alternative machine or treatment protocol changed will lead to the MRL protocol at that site to be judged not feasible.

次要结局

未报告次要终点

研究者

发起方
Institute of Cancer Research, United Kingdom
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验